ข่าวประชาสัมพันธ์ Eli Lilly and Company+Type 2 Diabetes

Zuellig Pharma Launches Lilly's Innovative Obesity and Diabetes Medicine in Thailand Mounjaro(R) (tirzepatide) will be available in the market from the end of May 2025

Zuellig Pharma, a leading healthcare solutions company in Asia, has announced that Mounjaro(R) (tirzepatide), the innovative obesity and diabetes medicine developed by Eli Lilly and Company, will be launched in Thailand at the end of May 2025. Zuellig Pharma holds the marketing authorization for Mounjaro(R) (tirzepatide) in Thailand, having been granted the distribution and promotion rights for the medicine by Eli Lilly and Company this year. Mounjaro(R) (tirzepatide) is a once-weekly

Allianz Ayudhya Assurance Public Company ... Allianz Ayudhya Reports Robust Q1 2025 Results, Outperforms Market with Growth Across All Channels — Allianz Ayudhya Assurance Public Company Limited has ...

Krungthai Card Public Company Limited (KT... KTC Strengthens Travel Strategy with AirAsia MOVE Partnership — Krungthai Card Public Company Limited (KTC) has joined hands with AirAsia MOVE, a one-stop...

As the 2025 United Nations Ocean Conferen... Thai Union Calls for Collective Ocean Action, Highlights Progress Through SeaChange(R) 2030 — As the 2025 United Nations Ocean Conference concludes in Nic...

Company targets total revenue growth rate... Dusit Thani Public Company Limited enters final stage of strategic roadmap to unlock value — Company targets total revenue growth rate of 25-30% in 2025. ...

NSTDA Partners with Thai-Owned Company to... NSTDA Partners with Thai-Owned Company to Launch "Acamp Carbon Accounting" Platform — NSTDA Partners with Thai-Owned Company to Launch "Acamp Carbon Accou...

Plan ahead and treat yourself to a stay t... Your perfect Bangkok stay starts with early bird deals at Staybridge Suites Bangkok Thonglor — Plan ahead and treat yourself to a stay that feels just lik...